Lupus News

CLEVELAND — Patients with rosacea, livedoid vasculopathy and allergic contact dermatitis present with a multitude of dermatologic symptoms that rheumatologists can easily misdiagnose as rheumatic diseases, according to Anthony Fernandez, MD, PhD, of the Cleveland Clinic.

DESTIN, Fla. — Interstitial pneumonia with autoimmune features may potentially be the newest category of undifferentiated connective tissue disease, according to Judith James, MD, PhD, of the Oklahoma Medical Research Foundation and the Oklahoma University Health Science Center.

DESTIN, Fla. — National and international vaccination recommendations for patients with systemic lupus erythematosus have been insufficiently implemented, with less than 30% receiving annual influenza vaccines and half failing to receive any pneumococcal vaccine, according to data presented at the 2019 North American Young Rheumatology Investigator Forum.

DESTIN, Fla. — Among the chief challenges in treating many connective tissue diseases is the significant amount of heterogeneity, particularly in systemic lupus erythematosus, according Judith A. James, MD, PhD, of the Oklahoma Medical Research Foundation.

DESTIN, Fla. — In a session here at Congress of Clinical Rheumatology, Joseph F. Merola, MD, MMSc, of Harvard Medical School and Brigham and Women’s Hospital, shared the dermatology approach to cutaneous lupus erythematosus, as well as valuable skin elements of dermatomyositis.

DESTIN, Fla. — The riskiest thing you can do, when it comes to managing treatments for patients with rheumatic diseases, is to “play it safe,” according to John J. Cush, MD, director of clinical rheumatology for Baylor Scott & White Research Institute and professor of medicine and rheumatology at Baylor University Medical Center at Dallas.

DESTIN, Fla. — In a session here, Ronald F. van Vollenhoven, MD, PhD, of the Amsterdam University Medical Center, discussed the clinical utility of biomarkers to diagnose, predict disease activity and guide treatment decisions in rheumatoid arthritis and systemic lupus erythematosus.

DESTIN, Fla. — JAK inhibitors and ustekinumab have emerged as promising treatments for systemic lupus erythematosus, and more research is required to help patients who continue to report a low quality of life despite recent advancements, according Ronald F. van Vollenhoven, MD, PhD, of the Amsterdam University Medical Center.

DESTIN, Fla. — Statins demonstrate a protective effect in patients with systemic lupus erythematosus regardless of cardiovascular disease risk factors, according to a data presented at the North American Young Rheumatology Investigator Forum.

DESTIN, Fla. — Treatment with hydroxychloroquine was associated with a 67% reduced risk for atrial fibrillation in patients with systematic lupus erythematosus, according to a presenter at the North American Young Rheumatology Investigator Forum.